FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379281569> ?p ?o ?g. }

• W4379281569 endingPage "e17574" @default.
• W4379281569 startingPage "e17574" @default.
• W4379281569 abstract "e17574 Background: This study investigated the effect of PARPi as maintenance therapy after 1st-line and 2nd-line chemotherapy on platinum sensitivity in patients with recurrent high-grade serous epithelial ovarian cancer (rHGSOC). Methods: 172 patients with rHGSOC at Zhejiang Cancer Hospital and Jiaxing Maternity and Child Health Care Hospital from Jan 2017 to Dec 2021were retrospectively analyzed. Patients who received PARPi as maintenance therapy after first-line chemotherapy were enrolled to the 1st-PARPi group (n=23), and subjects who did not receive PARPi maintenance therapy were enrolled to the 1st control group (n=105). Similarly, 2nd- PARPi group (had not use PARPi in first-line treatment n=30), 2nd-control group (n=89) were divided. To evaluate progression-free survival (PFS), the first progression to second progression (TTSP), the second progression to third progressio (TTTP), PFS between the second progression and the end of the second-line chemotherapy (PFSs), PFS between the third progression and the end of the third-line chemotherapy (PFSt) and to compare whether PARPi as maintenance therapy affects the platinum sensitivity of these patients. Results: PFSs in 1st-PARPi vs.1st-control group (median 5 vs. 11 m; p=0.0037). PFSt in 2nd-PARPi vs. 2nd-control group(median 4.5 vs. 9.0 m; p=0.0009). TTSP in 1st-PARPi vs. 1st-control group (median 11 vs. 16 m; p=0.0045). TTTP in 2nd-PARPi vs. 2nd-control group (median 10 vs. 15 m; p=0.0007). Among the 23 patients in 1st-PARPi group and 105 patients in 1st-control group, 9 and 99 patients were platinum sensitive while 14 and 6 patients were platinum resistant respectively (HR 14.46, 95% CI =4.07-51.53, P < 0.0001). Among the 30 patients in 2nd-PARPi group and 89 patients in 2nd-control group, 10 and 71 patients were platinum sensitive while and 20 and 18 patients were platinum resistant respectively (HR 4.37 95% CI=1.98-9.64, P < 0.0001). Age, stage, residual tumor after initial surgery treatment and the courses of platinum-based chemotherapy before PARPi,BRCA gene mutation were not the related factors affecting the platinum sensitivity of next line chemotherapy. There was no statistical difference in the effect of duration of PARPi on the platinum sensitivity of next line chemotherapy (duration of PARPi≥ 18 months vs. <18 months in 1st-PARPi group, HR 0.60, 95% CI=0.18-2.04, P=0.41; duration of PARPi≥ 12 months vs. <12 months in 2nd-PARPi group, HR 0.62, 95% CI=0.26-1.48, P=0.24, respectively). Conclusions: Patients with rHGSOC using PARPi affected the platinum sensitivity and were more likely to lead to platinum resistance no matter how long the during of PARPi were.This conclusion was consistent with the cross resistance between PARPi and platinum. Care should be taken when using PARPi after 1st-line and 2nd-line chemotherapy as maintenance therapy." @default.
• W4379281569 created "2023-06-05" @default.
• W4379281569 creator A5030760079 @default.
• W4379281569 creator A5080435466 @default.
• W4379281569 date "2023-06-01" @default.
• W4379281569 modified "2023-09-25" @default.
• W4379281569 title "Real world study on the effect of PARPi as maintenance therapy after first-line and second-line chemotherapy on platinum sensitivity in patients with recurrent high-grade serous epithelial ovarian cancer." @default.
• W4379281569 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e17574" @default.
• W4379281569 hasPublicationYear "2023" @default.
• W4379281569 type Work @default.
• W4379281569 citedByCount "0" @default.
• W4379281569 crossrefType "journal-article" @default.
• W4379281569 hasAuthorship W4379281569A5030760079 @default.
• W4379281569 hasAuthorship W4379281569A5080435466 @default.
• W4379281569 hasConcept C121608353 @default.
• W4379281569 hasConcept C126322002 @default.
• W4379281569 hasConcept C143998085 @default.
• W4379281569 hasConcept C150173356 @default.
• W4379281569 hasConcept C2776694085 @default.
• W4379281569 hasConcept C2780739268 @default.
• W4379281569 hasConcept C71924100 @default.
• W4379281569 hasConcept C90924648 @default.
• W4379281569 hasConceptScore W4379281569C121608353 @default.
• W4379281569 hasConceptScore W4379281569C126322002 @default.
• W4379281569 hasConceptScore W4379281569C143998085 @default.
• W4379281569 hasConceptScore W4379281569C150173356 @default.
• W4379281569 hasConceptScore W4379281569C2776694085 @default.
• W4379281569 hasConceptScore W4379281569C2780739268 @default.
• W4379281569 hasConceptScore W4379281569C71924100 @default.
• W4379281569 hasConceptScore W4379281569C90924648 @default.
• W4379281569 hasIssue "16_suppl" @default.
• W4379281569 hasLocation W43792815691 @default.
• W4379281569 hasOpenAccess W4379281569 @default.
• W4379281569 hasPrimaryLocation W43792815691 @default.
• W4379281569 hasRelatedWork W2018515503 @default.
• W4379281569 hasRelatedWork W2077295477 @default.
• W4379281569 hasRelatedWork W2139647583 @default.
• W4379281569 hasRelatedWork W2364439575 @default.
• W4379281569 hasRelatedWork W2540335153 @default.
• W4379281569 hasRelatedWork W2749809681 @default.
• W4379281569 hasRelatedWork W2984042894 @default.
• W4379281569 hasRelatedWork W3206225438 @default.
• W4379281569 hasRelatedWork W4281686870 @default.
• W4379281569 hasRelatedWork W4317566941 @default.
• W4379281569 hasVolume "41" @default.
• W4379281569 isParatext "false" @default.
• W4379281569 isRetracted "false" @default.
• W4379281569 workType "article" @default.